Board of Directors

Donald J. McCaffreyChairman of the Board

As President and Chief Executive Officer of Zenith, Mr. McCaffrey has 40+ years of corporate management experience including over 20 years in drug discovery and development. Don’s expertise in corporate operations has attracted an international team of experts, including world renowned oncology Key Opinion Leaders. He has facilitated many high-profile collaborations and partnerships with leading organizations including Pfizer, Newsoara BioPharm Co., Ltd. (Newsoara), National Cancer Institute (NCI), University of California San Francisco (UCSF) and Merck.

In addition to Zenith, Don serves as President and CEO of Resverlogix Corp. (TSX: RVX), (“Resverlogix”), a late-stage clinical biotechnology company. Resverlogix has the most advanced epigenetic drug, apabetalone, which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) in 2020, the first for a major cardiovascular indication. Zenith was spun out of Resverlogix in 2013.

Don is passionate about supporting local non-profit organizations, including: the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.

Kelly McNeill, B.COMM (HONS), M.ACC, C.A.Director

Mr. McNeill has over 20 years of experience in manufacturing and technology organizations, both large and small, with experience in M&A, raising capital in public equity markets and managing complex operations around the globe. McNeill is the CEO & CFO at RTDS Technologies Inc., a global provider of real time digital simulators to the power systems industry. Kelly has also served as Executive Vice President, Finance and Administration and Chief Financial Officer of IMRIS Inc. and Chief Financial Officer of Resverlogix Corp. Prior thereto, he held senior financial positions with two multinational companies, including General Manager of the Canadian operations for Haworth and Vice President of Finance for SMED.

Mr. McNeill holds a Masters of Accountancy and a Bachelor of Commerce (Honours), and is a Chartered Professional Accountant/Chartered Accountant. He also serves on the Board of Directors and Audit Committee of Resverlogix Corp.

Dr. Eldon R. Smith OC, MD, FRCPC, FCAHS, FAHA, FIACSDirector

Dr. Smith was Dean of the Faculty of Medicine at the University of Calgary from 1992 to 1997 and Editor-in-Chief of the Canadian Journal of Cardiology from 1997 to 2010. Dr. Smith’s research interests include circulatory mechanics, exercise physiology and echocardiography. He has published more than 250 papers and book chapters and has been a contributor to many national and international organizations; he has been President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges and Vice President of the Inter-American Society of Cardiology. He has served on a number of public boards including the Alberta Heritage Foundation for Medical Research, the Alberta Health Professions Advisory Board, and the Premier’s Advisory Council on Health in Alberta. He founded and served as President and Director of the Peter Lougheed Medical Research Foundation, a national initiative to support excellence in health research in Canada. He is chair of the Advisory Board of the Libin Cardiovascular Institute of Alberta and from 2006 to 2010 he was appointed by the Federal Government to chair the development of a National Strategy for Cardiovascular Health and Disease.

Dr. Smith also serves on the Board of Directors of Cardiol Therapeutics Inc.

Dr. Norman C.W. Wong, M.D., FRCPDirector

Dr. Wong is Co-founder and Chief Scientific Officer of Resverlogix Corp. Dr. Wong serves as Professor of Medicine, University of Calgary, a clinician and scientist who specializes in endocrinology, internal medicine, molecular biology, gene/cell therapy and regulation. His numerous academic accomplishments include over 300 published works, including extensive research in the field of epigenetics.

Dr. Wong has served as a medical consultant to Abbott Laboratories, Amgen, Astra Zeneca, B.I., Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Sanofi, and Solvay Pharmaceuticals in the areas of diabetes mellitus, thyroid disease, testosterone treatment and in the development of cholesterol lowering drugs. He is a Director of Zenith Epigenetics, and is a member of the Scientific Advisory Board at Sernova Corp. Dr. Wong’s academic record includes an Undergraduate B.Sc., Masters Degree in medical biochemistry, and a Medical Degree from the University of Calgary.

Kenneth J. ZuerblisDirector

Mr. Zuerblis was formerly Executive Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc., a position he held until May 2012. Prior to joining Savient, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President at ImClone Systems from 2008 through 2009. In that role, he was responsible for the strategic planning and leadership of finance and related operations and helped lead all aspects of the sale of the company to Eli Lilly and Company. From 1994 through 2005, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc., and held the position of Corporate Controller from 1991 through 1994. Enzon developed the first three FDA approved products using PEGylation technology. Most notably during Mr. Zuerblis’ 14 year tenure, Enzon transformed from an early stage biotechnology company into a fully integrated biopharmaceutical company with five marketed products.

He began his career at KPMG, LLP in 1982 where he held management positions of increasing responsibility over a 10 year period. Mr. Zuerblis brings nearly 30 years of proven leadership expertise in building fully integrated biopharmaceutical organizations and has an established track record of managing complex commercial and research organizations, raising capital, overseeing multifaceted merger and acquisition transactions, and directing all investor and shareholder relations.

Mr. Zuerblis earned his Bachelor of Science in Accounting from Seton Hall University and is a certified public accountant in the State of New Jersey.

Mr. Zuerblis also serves on the Board of Directors of Resverlogix Corp. and Stemline Therapeutics.